Program
Peptide-drug Conjugate BL0020
Its studies are mostly in Small Cell Lung Carcinoma, led by Shanghai Best-Link Bioscience.
Furthest: phase 2, since Feb 9, 20263 company-led studies, 3 open or runningNext primary completion: Dec 22, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shanghai Best-Link Bioscience | 33 open or running | phase 2since Feb 9, 2026 | May 24, 2023 | Dec 22, 2027phase 2 · NCT07414927 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 24, 2023First study: phase 1 study in Advanced Solid TumorFirst studyNCT05886868 · 66 planned · Australia, China
- Feb 9, 2026Phase 2 study in Small Cell Lung CarcinomaPhase 2 reachedNCT07414927 · 48 planned · China
- Apr 20, 2026Phase 1 study in Small Cell Lung CarcinomaNCT07550842 · 33 planned · China
Ahead
- Dec 22, 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT07414927
- Apr 28, 2028Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT07550842
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07550842Small Cell Lung Carcinoma · China | 1 | Not yet recruiting | Apr 28, 2028 | 33 |
| NCT07414927Small Cell Lung Carcinoma · China | 2 | Not yet recruiting | Dec 22, 2027 | 48 |
| NCT05886868Advanced Solid Tumor · Australia, China | 1 | Recruiting | Jul 2024 | 66 |
How it is read
Names in the registry
- “BL0020”, 3 entries
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.